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Summary
Background There is much uncertainty about the risks of leukaemia and lymphoma after repeated or protracted low-
dose radiation exposure typical of occupational, environmental, and diagnostic medical settings. We quantiﬁ ed 
associations between protracted low-dose radiation exposures and leukaemia, lymphoma, and multiple myeloma 
mortality among radiation-monitored adults employed in France, the UK, and the USA.
Methods We assembled a cohort of 308 297 radiation-monitored workers employed for at least 1 year by 
the Atomic Energy Commission, AREVA Nuclear Cycle, or the National Electricity Company in France, 
the Departments of Energy and Defence in the USA, and nuclear industry employers included in the 
National Registry for Radiation Workers in the UK. The cohort was followed up for a total of 8·22 million person-
years. We ascertained deaths caused by leukaemia, lymphoma, and multiple myeloma. We used Poisson regression 
to quantify associations between estimated red bone marrow absorbed dose and leukaemia and lymphoma 
mortality.
Findings Doses were accrued at very low rates (mean 1·1 mGy per year, SD 2·6). The excess relative risk of leukaemia 
mortality (excluding chronic lymphocytic leukaemia) was 2·96 per Gy (90% CI 1·17–5·21; lagged 2 years), most 
notably because of an association between radiation dose and mortality from chronic myeloid leukaemia (excess 
relative risk per Gy 10·45, 90% CI 4·48–19·65).
Interpretation This study provides strong evidence of positive associations between protracted low-dose radiation 
exposure and leukaemia.
Funding Centers for Disease Control and Prevention, Ministry of Health, Labour and Welfare of Japan, Institut de 
Radioprotection et de Sûreté Nucléaire, AREVA, Electricité de France, National Institute for Occupational Safety and 
Health, US Department of Energy, US Department of Health and Human Services, University of North Carolina, 
Public Health England.
Copyright © Leuraud et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Although exposure to high-dose ionising radiation is rare 
outside of radiotherapy, repeated or protracted low-dose 
exposure has become increasingly common over the past 
25 years.1 Occupational and environmental sources of 
radiation exposure are important; however, the largest 
contributor to this trend is medical radiation exposure. 
In 1982, the average yearly dose of ionising radiation 
from medical exposures was about 0·5 mGy per person 
in the USA; by 2006, it had increased to 3·0 mGy.2 
A similar pattern exists in other high-income countries: 
use of diagnostic procedures involving radiation in the 
UK more than doubled over that period3 and more than 
tripled in Australia.4 Because ionising radiation is a 
carcinogen,5 its use in medical practice must be balanced 
against the risks associated with patient exposure.6
The primary basis for estimating cancer risks from 
ionising radiation exposures are epidemiological studies 
of Japanese survivors of the atomic bombings of 
Hiroshima and Nagasaki in August, 1945.7 Within a few 
years of the bombings there was evidence of an excess of 
leukaemia, predominantly myeloid subtypes, among the 
survivors.8–12 These ﬁ ndings helped to establish that 
ionising radiation causes leukaemia.13 However, this 
evidence mostly relates to acute high-dose exposure. The 
risks associated with protracted or repeated low-dose 
exposures are more relevant to the public and health 
practitioners.
The International Nuclear WORKers Study 
(INWORKS) was done to strengthen the scientiﬁ c basis 
for protecting people from low-dose protracted or 
intermittent radiation exposure. It included workers 
from France,14 the UK,15 and the USA16 who have been 
monitored for external exposure to radiation with 
personal dosimeters and followed up for up to 60 years 
after exposure. Here, we report data for leukaemia, 
lymphoma, and multiple myeloma mortality among 
participants of INWORKS.
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Methods
Study design and participants
The INWORKS cohort consists of nuclear workers from 
three of the major partners included in the previously 
published 15-country study of cancer among workers in 
the nuclear industry:17 France,14 the UK,15 and the USA.16 
Less than 20% of deaths from leukaemia were contributed 
by the other 12 countries.18 These cohorts have been 
updated since the 15-country study. INWORKS includes 
fewer partners than the earlier 15-country study because 
of the limited resources and the consequent need for 
eﬃ  ciency in project coordination.
The study includes workers employed by the French 
Atomic Energy Commission, AREVA Nuclear Cycle, and 
Electricité de France, workers employed by the British 
Atomic Weapons Establishment, British Nuclear Fuels, 
the UK Atomic Energy Authority, British Energy 
Generation, the UK Ministry of Defence, and other 
organisations providing data to the National Registry for 
Radiation Workers, and workers employed by the US 
Department of Energy’s Hanford Site, Savannah River 
Site, Oak Ridge National Laboratory, Idaho National 
Laboratory, and the Portsmouth Naval Shipyard. Workers 
who were employed in the nuclear industry for less than 
1 year were excluded. In France, workers were given the 
opportunity to refuse participation, which is required by 
the French Data Protection Authority; however, none did. 
In the USA, worker information was taken from existing 
records, with no direct contact with any participants; 
because there is minimal risk to participants, the 
National Institute for Occupational Safety and Health 
institutional review board waived requirements for 
informed consent. UK workers can refuse to participate 
in the National Registry for Radiation Workers and 
associated studies; less than 1% did. 
Procedures
Participants were followed up for a total of 8·22 million 
person-years to ascertain vital status up to 2004 in France, 
2001 in the UK, and 2005 in the USA. Underlying cause 
of death was abstracted from death certiﬁ cates and 
generally coded according to the revision of the 
International Classiﬁ cation of Diseases (ICD) in eﬀ ect at 
the time of death. We assessed leukaemia other than 
chronic lymphocytic leukaemia (CLL; ICD9 codes 
204–208 excluding 204.1 and 204.9), acute myeloid 
leukaemia (ICD9 codes 205.0, 206.0, 207.0, and 207.2), 
chronic myeloid leukaemia (ICD9 code 205.1), acute 
lymphoblastic leukaemia (ICD9 code 204.0), and CLL 
(ICD9 code 204.1). We assessed lymphoma deaths 
separately for non-Hodgkin lymphoma (ICD9 codes 200, 
202, 273.3), Hodgkin’s lymphoma (ICD9 code 201), and 
multiple myeloma (ICD9 code 203). The appendix (p 2) 
shows an exhaustive list of ICD codes. 
Data for monitoring exposure to ionising radiation 
were available from dose registry, government, and 
company records, providing individual yearly estimates 
of whole-body exposure to external penetrating radiation 
(primarily γ rays). Red bone marrow absorbed doses 
expressed in Gy were derived by dividing recorded 
external penetrating radiation dose estimates by the 
appropriate organ dose conversion factor.19,20 In this 
report, dose indicates absorbed dose to red bone marrow 
expressed in Gy. Because most external exposures were 
to high-energy photons, with a radiation weighting factor 
of 1·0, absorbed dose in Gy could be expressed in terms 
of equivalent dose in Sieverts.
Statistical analysis
Participants entered the study either 1 year after the date of 
ﬁ rst employment or on the date of ﬁ rst dosimetric 
monitoring, whichever was later. In France, the national 
death registry recorded information on individual causes 
of death only since 1968; therefore, French workers entered 
follow-up on Jan 1, 1968, or later. Participants remained in 
the study until the earliest of date of death, date lost to 
follow-up, or end of follow-up. We estimated relative risk 
(RR) by a model of the form RR=1 + βd, generally used in 
studies of radiation eﬀ ects,21 where d is the dose and β is an 
estimate of the excess relative risk (ERR; RR – 1) per unit 
dose; we derived likelihood-based CIs. All models were 
stratiﬁ ed by country, sex, calendar period (<1946, 1946–50…
Research in context
Evidence before this study
Ionising radiation causes leukaemia. The primary quantitative 
basis for radiation protection standards comes from studies of 
populations exposed to acute, high doses of ionising radiation. 
Although previous studies of nuclear workers addressed 
leukaemia radiogenicity, questions remain about the size of the 
risk from protracted radiation exposure in occupational settings.
Added value of this study
We report a positive dose–response relationship between 
cumulative, external, protracted, low-dose exposure to ionising 
radiation, and subsequent death caused by leukeamia (excluding 
chronic lymphocytic leukaemia). The risk coeﬃ  cient per unit dose 
was consistent with those derived from analyses of other 
populations exposed to higher radiation doses and dose rates.
Implications of all the available evidence
The present study provides strong evidence of a positive 
association between radiation exposure and leukaemia even for 
low-dose exposure. This ﬁ nding shows the importance of 
adherence to the basic principles of radiation protection—to 
optimise protection to reduce exposures as much as reasonably 
achievable and—in the case of patient exposure—to justify that 
the exposure does more good than harm. 
See Online for appendix
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1996–2000, ≥2001), and age (<35, 35–39…70–74, ≥75); these 
potential confounders were selected a priori from a set of 
measured covariates. We also ﬁ tted linear-quadratic and 
pure-quadratic functions of dose and selected a model 
with Akaike information criterion.22
To allow for an induction and latency period between 
exposure to radiation and death, cumulative doses were 
lagged by 2 years for analyses of leukaemia mortality and 
by 10 years for analyses of lymphoma and multiple 
myeloma. These lag assumptions were chosen a priori. 
In sensitivity analyses we assessed a 10-year lag for 
analyses of leukaemia mortality and a 2-year lag for 
analyses of lymphoma and multiple myeloma, ﬁ tted 
models to restricted ranges of dose, and excluded 
workers with substantial doses from neutrons (ie, 
workers with recorded cumulative neutron doses 
exceeding 10% of the total equivalent dose for external 
radiation). To provide empirical support for the absence 
of confounding by socioeconomic status, we report 
supplementary analyses adjusted for socioeconomic 
status (based on job title: managers and engineers, 
administrative staﬀ , skilled workers, unskilled workers, 
uncertain); and, to address concern about potential 
confounding by internal contamination, we report 
analyses adjusted for known or suspected internal 
radiation exposure. We did the analyses excluding one 
country at a time to assess the eﬀ ect of a single country 
on overall results. Because the objective of most 
contemporary radiation epidemiological studies is to 
investigate the potential for an increased cancer risk in 
relation to radiation exposure, one-sided p values and 
corresponding 90% CIs are usually presented; we follow 
that convention here by reporting 90% CIs. All models 
were ﬁ tted with EPICURE software.23
Role of the funding source
The funders had no role in study design, data analysis, 
data interpretation, or writing of the report. AREVA and 
Électricité de France provided historical occupational 
data and individual monitoring data for part of the 
French cohort. KL, DBR, and MM had full access to all 
the data in the study. KL and DBR had ﬁ nal responsibility 
for the decision to submit for publication.
Results
We assembled a cohort of 308 297 radiation-monitored 
workers. Table 1 shows the characteristics of the study 
population. Mean follow-up was 27 years (SD 12) and 
nearly 22% of the workers were deceased at the end of 
follow-up. Mean cumulative dose was 16 mGy. The median 
was 2·1 mGy (IQR 0·3–11·7), with a tenth percentile of 
0·0 mGy and a 90th percentile of 40·8 mGy (appendix p 1). 
The mean yearly dose was 1·1 mGy (SD 2·6).
We recorded 531 deaths caused by leukaemia excluding 
CLL, 814 caused by lymphoma, and 293 caused by multiple 
myeloma. 281 (53%) of 531 deaths caused by leukaemia 
excluding CLL occurred in people who had accrued less 
than 5 mGy (appendix p 3). The RR of death caused by 
France USA UK Overall
Study period 1968–2004 1944–2005 1946–2001 1944–2005
Number of participants 59 003 101 428 147 866 308 297
Person-years (millions) 1·47 3·34 3·41 8·22
Duration of follow-up (years)
Mean (SD) 25 (9) 33 (13) 23 (12) 27 (12)
Median (IQR) 23 (18–36) 31 (23–44) 22 (14–32) 26 (18–36)
Age at last observation (years)
Mean (SD) 56 (13) 65 (13) 54 (15) 58 (15)
Median (IQR) 54 (46–66) 66 (55–76) 54 (42–66) 58 (47–70)
Sex
Male 51 567 (87%) 81 883 (81%) 134 812 (91%) 268 262 (87%)
Female 7436 (13%) 19 545 (19%) 13 054 (9%) 40 035 (13%)
Vital status on Dec 31, 2005
Alive 52 565 (89%) 65 573 (65%) 118 775 (80%) 236 913 (77%)
Died 6310 (11%) 35 015 (35%) 25 307 (17%) 66 632 (22%)
Number of deaths from malignant neoplasm of 
lymphoid and haemopoietic tissues (% of total 
deaths)
196 (3%) 1031 (3%) 564 (2%) 1791 (3%)
Emigrated or lost to follow-up 128 (<1%) 840 (1%) 3784 (3%) 4752 (2%)
Cumulative red bone marrow dose (mGy)
Mean (range) 11·6 (0·0–415·8) 15·2 (0·0–820·2) 18·2 (0·0–1217·5) 15·9 (0·0–1217·5)
Median (IQR) 1·3 (0·0–10·7) 1·9 (0·2–10·6) 2·6 (0·4–12·9) 2·1 (0·3–11·7)
Data are n (%) unless stated otherwise. 
Table 1: Characteristics of individuals included in INWORKS
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leukaemia excluding CLL by categories of cumulative dose 
showed a substantial risk for cumulative dose above 
200 mGy (appendix p 3). The estimated ERR of mortality 
caused by leukaemia excluding CLL was 2·96 per Gy 
(90% CI 1·17–5·21; table 2). The trend in the ERR of 
leukaemia excluding CLL with dose was well described by 
a simple linear function of cumulative dose; inclusion of a 
higher order polynomial function (ie, a linear-quadratic or 
pure-quadratic function of dose) did not substantially 
improve the model ﬁ t (the Akaike information criterion 
was lowest for the pure-quadratic model but only diﬀ ered 
by 0·3 from that of the linear model; data not shown). The 
ERR of leukaemia excluding CLL was not attenuated 
when restricted to doses of less than 300 mGy or less than 
100 mGy (ﬁ gure); however, 90% CIs were much wider 
when based on data for the restricted dose range.
We assessed the associations between cumulative dose 
and subtypes of leukaemia. We detected positive 
associations for chronic myeloid leukaemia, acute 
myeloid leukaemia, and acute lymphoblastic leukaemia; 
the association was largest for chronic myeloid leukaemia 
(table 2). Associations also were positive but highly 
imprecise for Hodgkin’s lymphoma, non-Hodgkin 
lymphoma, and multiple myeloma with CIs that spanned 
zero (table 2). The association between radiation dose 
and CLL mortality was negative (table 2).
Alternative lag assumptions resulted in little change in 
the ERR per Gy (appendix p 4). When adjusting the ERR 
model for socioeconomic status, the ERR per Gy was 
practically unchanged for leukaemia excluding CLL and 
for chronic myeloid leukaemia (appendix p 5). Similarly, 
adjustment for internal radiation con tamination had 
little eﬀ ect (appendix p 5). We assessed the eﬀ ect of 
excluding people who had recorded neutron exposures; 
we showed a positive association for leukaemia excluding 
CLL (ERR per Gy 4·19, 90% CI 1·42–7·80, 453 deaths) 
and chronic myeloid leukaemia (ERR per Gy 9·55, 
90% CI 2·39–21·7, 79 deaths). To assess whether any 
single country substantially aﬀ ected the results, we 
assessed radiation-mortality associations excluding one 
country at a time (appendix p 6). The estimated ERR 
per Gy for leukaemia excluding CLL was 2·95 
(90% CI 1·13–5·24) when excluding France, 2·32 
(0·03–5·33) when excluding the UK, and 3·68 
(1·09–7·29) when excluding the USA (appendix p 6). For 
multiple myeloma and Hodgkin’s lymphoma, the 
associations could not be estimated when excluding the 
USA, but the multiple myeloma was positive when 
excluding the UK (ERR per Gy 3∙32 [90% CI 0∙27–7∙64]).
Discussion
We showed a positive association between cumulative 
dose of ionising radiation and death caused by leukaemia 
(excluding CLL) among adults who were typically exposed 
to low doses. The association was greatest for chronic 
myeloid leukaemia, with positive but imprecise dose–
response for deaths caused by acute myeloid leukaemia, 
acute lymphoblastic leukaemia, Hodgkin’s lymphoma, 
non-Hodgkin lymphoma, and multiple myeloma.
The estimated association between cumulative 
radiation dose with a 2-year exposure lag assumption 
and death caused by leukaemia excluding CLL was 
similar in size and precision to the linear dose–response 
estimate for male atomic bomb survivors exposed 
between the ages of 20 and 60 years (ERR at 1 Sv 2·63, 
90% CI 1·50–4·27).14 Although based on a substantially 
lower dose distribution than in analyses of atomic bomb 
survivors, typically with very low doses accrued over a 
long period, the similar size of the associations supports 
contemporary estimates of risk of leukaemia after adult 
exposure to radiation. This is notable because our 
estimates were not extrapolated from data for acute 
exposures.
In previous analyses of cancer among workers in 
15 countries,18 the association between mortality for 
leukaemia excluding CLL and cumulative radiation dose 
Figure: Relative risk of leukaemia excluding chronic lymphocytic leukaemia associated with 2-year lagged 
cumulative red bone marrow dose 
The lines are the ﬁ tted linear dose–response model and the shading represents the 90% CIs. 
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Red bone marrow dose (mGy)
Entire range
<300 mGy
<100 mGy
Deaths ERR per Gy 90% CI
Leukaemia excluding CLL* 531 2·96 1·17 to 5·21
Chronic myeloid leukaemia* 100 10·45 4·48 to 19·65
Acute myeloid leukaemia* 254 1·29 –0·82 to 4·28
Acute lymphoblastic leukaemia* 30 5·80 NE to 31·57
CLL* 138 –1·06 NE to 1·81
Multiple myeloma† 293 0·84 –0·96 to 3·33
Non-Hodgkin lymphoma† 710 0·47 –0·76 to 2·03
Hodgkin’s lymphoma† 104 2·94 NE to 11·49
ERR estimated with a linear model stratiﬁ ed by country, calendar period, sex, and age. NE lower CI bound could not be 
estimated because it was on the boundary of the parameter space (–1/maximum dose). 14 deaths were assigned ICD9 
code 204.9 (lymphoid leukaemia, unspeciﬁ ed) and one death was assigned ICD9 code 202.9 (other and unspeciﬁ ed 
malignant neoplasms of lymphoid, haemopoietic, and related tissue) were excluded from the cause-speciﬁ c analyses. 
*2-year lagged cumulative dose. †10-year lagged cumulative dose. ERR=excess relative risk. CLL=chronic lymphocytic 
leukaemia. NE=not estimable. 
Table 2: ERR per Gy of cumulative red bone marrow dose for causes of death
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with a 2-year exposure lag assumption (ERR per Sv 1·93, 
90% CI <0–7·14) was smaller and much less precise than 
the estimate we obtained in our pooled analysis of three 
countries. The gain in precision is a result of the larger 
number of deaths from leukaemia excluding CLL in 
INWORKS (n=531) compared to the earlier study (n=196), 
because of longer follow-up (mean follow-up in INWORKS 
was 27 years vs 13 years in the 15-country study17) and the 
enlargement of the French, UK, and US cohorts compared 
with previous analyses.14–16 Moreover, the 15-country study 
excluded people with potential exposures from neutron 
and internal contamination. In our study, we included 127 
deaths caused by leukaemia excluding CLL for workers 
with potential exposure to neutron and internal 
contamination. Similarly, the risk estimate for non-
Hodgkin lymphoma in the INWORKS study was more 
precise than the estimate reported in the 15-country 
study,24 again because the present study included more 
deaths (248 in the 15-country study, 710 in the present 
study). The CIs do not overlap for estimated associations 
between radiation dose and death caused by acute and 
chronic myeloid leukaemia; a formal test of heterogeneity 
in associations by leukaemia subtype would require a joint 
modelling approach and was not used here.
We did not ﬁ nd any eﬀ ect of a single country on the 
estimated association for leukaemia excluding CLL. For 
multiple myeloma, the association was signiﬁ cantly 
positive when only the UK data were excluded, suggesting 
a possible heterogeneity in the risk pattern between the 
three cohorts. Schubauer-Berigan and colleagues16 
reported a signiﬁ cant increased risk of multiple myeloma 
mortality associated with dose in their analysis of the 
USA cohort (ERR per 10 mSv 3·9, 90% CI 0·6–9·6), 
whereas no signiﬁ cant dose-related excess was detected 
in the third analysis of the UK National Registry for 
Radiation Workers (although a signiﬁ cant excess risk was 
recorded in an analysis of incidence).15 Multiple myeloma 
has a potentially long period of development of up to 
20 years. The older age at the end of follow-up in the 
USA cohort might explain the heterogeneity.
We tried to reduce uncertainties in dose estimates that 
could bias dose–response analyses.20 Nevertheless, occupa-
tional radiation dose estimates are prone to measurement 
error; consequently, exposure mis classiﬁ cation is an 
unavoidable study limitation. Outcome misclassiﬁ cation 
is also a potential concern in studies that rely on death 
certiﬁ cates for classiﬁ cation of leukaemia and lymphoma 
by subtype. This concern is well known for CLL, for which 
incidence studies seem more appropriate.25–28 Poor 
sensitivity and imperfect speciﬁ city of death certiﬁ cates 
might reduce statistical precision and induce bias in 
analyses of subtypes. However, death certiﬁ cate 
information remains a valuable resource for this type of 
cohort investigation.
There are few potential confounders of the associations 
under study. For example, smoking causes myeloid 
leukaemia;29,30 however, the size of this association is 
relatively small31 and therefore would require large 
diﬀ erences in smoking across levels of cumulative dose to 
cause substantial confounding of the radiation–leukaemia 
association. Moreover, adjusting risk analyses by socio-
economic status would reduce substantial confounding by 
smoking.32 Adjustment for socioeconomic status resulted 
in little change in the risk estimate for leukaemia excluding 
CLL. Exposure of nuclear workers to other causes of 
leukaemia such as benzene29,30 cannot be excluded as a 
potential source of bias, even though benzene was not 
widely used in the nuclear industry. In a previous analysis 
of US nuclear workers, Schubauer-Berigan and coworkers33 
reported weak evidence of confounding by benzene 
exposure when analysing leukaemia risk associated with 
external radiation exposure. Benzene exposure could not 
be assessed for the INWORKS study. Internal exposures to 
radionuclides—notably uranium and plutonium—
occurred at the study sites, and we did not evaluate doses 
from these intakes. However, our sensitivity analyses 
showed that internal contamination might have little eﬀ ect 
on the relation between external radiation exposure and 
leukaemia risk. These results are consistent with the 
conclusions of Shilnikova and colleagues,34 who reported 
no indication of any eﬀ ect of internal contamination on 
leukaemia mortality among nuclear workers, whereas the 
risk of leukaemia was positively associated with external 
γ-ray exposure.
Medical workers are also exposed to low doses of 
external γ-rays or x-rays. No study has provided estimates 
of leukaemia risk for medical workers because accurate 
historical dosimetry data are not available for these 
populations.35 Liu and colleagues36 estimated mortality in 
a cohort of 90 268 USA radiological technologists. They 
reported that the leukaemia risk was doubled for 
technologists who had worked for more than 30 years 
compared with those who had worked for less than 
10 years, but the cohort did not provide any information 
about doses received by the workers.
In summary, this study provides strong evidence of an 
association between protracted low dose radiation exposure 
and leukaemia mortality. At present, radiation protection 
systems are based on a model derived from acute 
exposures, and assumes that the risk of leukaemia per unit 
dose progressively diminishes at lower doses and dose 
rates.37 Our results provide direct estimates of risk per unit 
of protracted dose in ranges typical of environmental, 
diagnostic medical, and occupational exposure.
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